**Core tip:** We explored methylated-differentially expressed genes in hepatocellular carcinoma (HCC) using a series of bioinformatics databases and tools. In total, we categorized 266 genes as hypermethylated, lowly expressed genes (Hyper-LGs) referring to endogenous and hormone stimulus, as well as 161 hypomethylated, highly expressed genes (Hypo-HGs) referring to DNA replication and metabolic process. Pathway analysis showed Hyper- LGs were mainly enriched in cancer, while Hypo-HGs were essentially related to cell cycle. Finally, we identified hub genes that might be utilized as biomarkers based on aberrant methylation, which might be useful for the accurate diagnosis and treatment of HCC.

INTRODUCTION
============

Hepatocellular carcinoma (HCC), as the most frequent type of liver cancer, is one of the main aggressive malignant cancers worldwide and the third leading cause of cancer-related deaths\[[@B1],[@B2]\]. HCC embodies a complicated, multi-step disease, and the processes involved are related to genomic amplifications, deletions, insertions, or mutations to induce a series of epigenetic and genetic alterations. Despite significant advances in early diagnosis and interventional therapies with the development of surgical and treatment approaches, most HCC patients are usually diagnosed at an advanced stage of cancer progression with a low 5-year survival rate and poor prognosis\[[@B3],[@B4]\]. Therefore, a better understanding of the molecular mechanisms and functional pathways of HCC and the development of new critical gene targets for early HCC detection are urgently needed.

Tumor epigenetics, acknowledged as inherited modifications in gene expression, encompasses DNA methylation, noncoding RNA, and histone acetylation\[[@B5]\]. DNA methylation is the main epigenetic modification, affecting independent loci in gene transcriptional regulation and preserving genome stability. A variety of tumors have a special deregulation signature that is characterized by aberrant DNA methylation\[[@B6]\]. Altered methylation in DNA sequences, including hypomethylation of oncogenes and hypermethylation of tumor suppressor genes, are regarded as a key event in carcinogenesis, including in HCC\[[@B7]-[@B9]\]. Thus, the detection of methylated-differentially expressed genes (MDEGs) and a better understanding of their characteristics may be useful for discovering the molecular mechanism and pathogenesis of HCC.

Previous studies have shown by analyzing profiling arrays that the pathogenesis of HCC is a complicated biological process involving epigenetic and genetic changes\[[@B10]-[@B12]\]. However, most of the above studies mainly focused on either gene expression or methylation data and did not perform a conjoint analysis. Methylated expressed genes can be detected concurrently by joining gene expression and methylation microarray data, thus allowing us to identify more accurately biological characteristics of HCC\[[@B13],[@B14]\]. In the present study, we explored the interaction network of differentially expressed genes (DEGs) and differentially methylated genes (DMGs) along with interrelated signalling pathways in HCC by analyzing the expression profile of gene expression microarray data (GSE25097) and gene methylation microarray data (GSE57956) using bioinformatics tools. We aimed to identify novel insights into the biological characteristics and pathways of MDEGs in HCC and make notional viewpoints available for the development and progression of HCC.

MATERIALS AND METHODS
=====================

Microarray data
---------------

We identified MDEGs between adjacent non-tumor samples and HCC samples by analyzing mRNA microarray and methylation profiling datasets. One gene expression profiling dataset, GSE25097, and another gene methylation dataset, GSE57956, were downloaded from Gene Expression Omnibus (GEO, [www.ncbi.nlm.nih.gov/geo/](www.ncbi.nlm.nih.gov/geo/)). In total, 243 adjacent non-tumor samples and 268 HCC tumor samples were registered in GSE25097 (platform: GPL10687 Rosetta/Merck Human RSTA Affymetrix 1.0 microarray, Custom CDF). For the gene methylation microarray data, GSE57956 was comprised entirely of 59 adjacent non-tumor tissues and 61 HCC tumor tissues \[platform: GPL8490 Illumina HumanMethylation27 BeadChip (HumanMethylation27_270596_v.1.2)\].

Data processing
---------------

We used an online tool, GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>), to analyze the differential expression by comparing two groups of samples across setup conditions in a GEO series. In the study, we used *P* \< 0.05 and \|fold change\| \> 2 as the cut-off standard to define the DEGs and DMGs. "MATCH function" was performed to categorize overlapping MDEGs between the GSE25097 and GSE57956 data sets. Finally, overlapping down-regulated and hypermethylation genes were identified as hypermethylated, lowly expressed genes (Hyper-LGs); similarly, overlapping up-regulated and hypomethylation genes were considered hypomethylated, highly expressed genes (Hypo-HGs).

Functional and pathway enrichment analysis
------------------------------------------

DAVID (the database for annotation, visualization and integrated discovery, https://david.ncifcrf.gov/) is an online tool for functional annotation and enrichment analysis to reveal biological features related to large gene lists\[[@B15]\]. Gene ontology (GO) analysis, including biological process, cellular component, and molecular function, is a main bioinformatics analysis method for annotating genes\[[@B16]\]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) is a database used to obtain high-level functions and utilities of the biological system originated from genome sequencing or high-throughput experimental technologies\[[@B17]\]. GO function and KEGG pathway enrichment analyses were performed for MDEGs using DAVID. A *P*-value \< 0.05 was considered as statistically significant.

Protein-protein interaction network generation and module analysis
------------------------------------------------------------------

We built a protein-protein interaction (PPI) network of Hyper-LGs and Hypo-HGs using the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, <http://string-db.org/>) database. STRING is an online database used to predict PPI\[[@B18]\], which is essential for recognizing the mechanisms of cell activities at the molecular level in cancer progressions. The cut-off standard was defined as an interaction score (median confidence) of 0.4. Consequently, the PPI network was visualized by Cytoscape (<http://www.cytoscape.org/>), and hub genes were ranked by cytoHubba. Molecular Complex Detection (MCODE) analysis was performed to screen modules within the PPI network in Cytoscape software. A MCODE score \> 4 and number of nodes \> 5 were taken as the criteria to define a module.

RESULTS
=======

Screening of MDEGs in HCC
-------------------------

Online analysis was performed by GEO2R software to identify DEGs or DMGs. By comparing the 1873 DEGs (676 up-regulated genes and 1197 down-regulated genes) with the 7242 DMGs (2652 hypermethylated genes and 4590 hypomethylated genes), we categorized 266 Hyper-LGs and 161 Hypo-HGs in GO, KEGG, and PPI analyses. The flowchart is presented in Figure [1](#F1){ref-type="fig"}.

![Flowchart of bioinformatics analysis. DMGs: Differentially methylated genes; DEGs: Differentially expressed genes; Hyper-LGs: Hypermethylated, lowly expressed genes; Hypo-HGs: Hypomethylated, highly expressed genes.](WJG-24-2605-g001){#F1}

GO functional enrichment analysis
---------------------------------

GO enrichment analysis was performed by DAVID, and the results are shown in Table [1](#T1){ref-type="table"}. For Hyper-LGs, enriched biological processes (BP) included response to endogenous and hormone stimulus, cell surface receptor linked signal transduction, and behavior. Cell component (CC) mainly displayed extracellular region and plasma membrane part, intrinsic to plasma membrane. Additionally, molecular function (MF) enrichment indicated glycosaminoglycan, pattern and polysaccharide binding, and protein tyrosine kinase activity as important related processes. Hypo-HGs were enriched in BP of DNA replication and metabolic process, cell division and cycle, and chromosome organization. CC was mainly involved in chromosome, chromatin, and and extracellular region part. With regards to MF, enrichments were focused on peptidase and enzyme inhibitor activity, phosphorus-oxygen lyase and cyclase activity, as well as cytoskeletal protein binding.

###### 

GO enrichment analysis of methylated-differentially expressed genes related with hepatocellular carcinoma

  **Category**   **Term**        **Count**                                                             **%**   ***P* value**   
  -------------- --------------- --------------------------------------------------------------------- ------- --------------- ----------
  Hyper-LGs      GOTERM_BP_FAT   GO:0048545\~response to steroid hormone stimulus                      18      6.79            1.51E-08
                 GOTERM_BP_FAT   GO:0009725\~response to hormone stimulus                              24      9.06            3.15E-08
                 GOTERM_BP_FAT   GO:0007166\~cell surface receptor linked signal transduction          60      22.64           1.75E-07
                 GOTERM_BP_FAT   GO:0009719\~response to endogenous stimulus                           24      9.06            1.89E-07
                 GOTERM_BP_FAT   GO:0007610\~behavior                                                  25      9.43            6.76E-07
                 GOTERM_CC_FAT   GO:0044421\~extracellular region part                                 48      18.11           1.97E-11
                 GOTERM_CC_FAT   GO:0005886\~plasma membrane                                           107     40.38           9.53E-10
                 GOTERM_CC_FAT   GO:0005576\~extracellular region                                      68      25.66           1.10E-08
                 GOTERM_CC_FAT   GO:0044459\~plasma membrane part                                      71      26.79           3.27E-08
                 GOTERM_CC_FAT   GO:0031226\~intrinsic to plasma membrane                              47      17.74           1.22E-07
                 GOTERM_MF_FAT   GO:0005539\~glycosaminoglycan binding                                 11      4.15            7.78E-05
                 GOTERM_MF_FAT   GO:0004714\~transmembrane receptor protein tyrosine kinase activity   8       3.02            8.88E-05
                 GOTERM_MF_FAT   GO:0001871\~pattern binding                                           11      4.15            1.72E-04
                 GOTERM_MF_FAT   GO:0030247\~polysaccharide binding                                    11      4.15            1.72E-04
                 GOTERM_MF_FAT   GO:0004713\~protein tyrosine kinase activity                          11      4.15            3.15E-04
                                                                                                                               
  Hypo-HGs       GOTERM_BP_FAT   GO:0006260\~DNA replication                                           10      6.25            6.22E-05
                 GOTERM_BP_FAT   GO:0051301\~cell division                                             12      7.50            8.37E-05
                 GOTERM_BP_FAT   GO:0051276\~chromosome organization                                   15      9.38            1.41E-04
                 GOTERM_BP_FAT   GO:0006259\~DNA metabolic process                                     15      9.38            2.19E-04
                 GOTERM_BP_FAT   GO:0007049\~cell cycle                                                19      11.88           2.44E-04
                 GOTERM_CC_FAT   GO:0005694\~chromosome                                                14      8.75            3.77E-04
                 GOTERM_CC_FAT   GO:0044427\~chromosomal part                                          12      7.50            1.01E-03
                 GOTERM_CC_FAT   GO:0000793\~condensed chromosome                                      7       4.38            1.34E-03
                 GOTERM_CC_FAT   GO:0000785\~chromatin                                                 8       5.00            2.77E-03
                 GOTERM_CC_FAT   GO:0044421\~extracellular region part                                 19      11.88           3.60E-03
                 GOTERM_MF_FAT   GO:0030414\~peptidase inhibitor activity                              6       3.75            1.24E-02
                 GOTERM_MF_FAT   GO:0016849\~phosphorus-oxygen lyase activity                          3       1.88            1.65E-02
                 GOTERM_MF_FAT   GO:0009975\~cyclase activity                                          3       1.88            1.80E-02
                 GOTERM_MF_FAT   GO:0004857\~enzyme inhibitor activity                                 7       4.38            3.53E-02
                 GOTERM_MF_FAT   GO:0008092\~cytoskeletal protein binding                              10      6.25            3.83E-02

Top five terms were listed on the basis of *P* value if over five terms in the category, Hyper-LGs (hypermethylated, lowly expressed genes), Hypo-HGs (hypomethylated, highly expressed genes).

KEGG pathway analysis
---------------------

The results of the KEGG pathway enrichment analysis implied that Hyper-LGs demonstrated enrichment in pathways of complement and coagulation cascades, dilated cardiomyopathy, cancer, Wnt, and chemokine signalling pathways. Hypo-HGs were significantly involved in cell cycle and steroid hormone biosynthesis pathways (Table [2](#T2){ref-type="table"}).

###### 

KEGG pathway analysis of methylated-differentially expressed genes related with hepatocellular carcinoma

  **Category**   **Term**       **Count**                                      **%**   ***P* value**   **Gene**   
  -------------- -------------- ---------------------------------------------- ------- --------------- ---------- -------------------------------------------------------------------------------------------------------
  Hyper-LGs      KEGG_PATHWAY   hsa04610:Complement and coagulation cascades   7       2.64            6.62E-03   *C7, CR1, CD55, THBD, MASP1, SERPINE1, PLAUR*
                 KEGG_PATHWAY   hsa05414:Dilated cardiomyopathy                7       2.64            2.50E-02   *LAMA2, ITGA9, ADCY1, ADRB1, ITGB8, ADCY5, TGFB3*
                 KEGG_PATHWAY   hsa05200:Pathways in cancer                    15      5.66            2.94E-02   *FGFR2, PTGS2, FLT3, PIK3CD, FZD1, TGFB3, MMP2, WNT2, LAMA2, RAC2, NKX3-1, LAMC2, WNT11, HHIP, GSTP1*
                 KEGG_PATHWAY   hsa04310:Wnt signaling pathway                 9       3.40            3.16E-02   *WNT2, SFRP5, NKD2, RAC2, PRICKLE1, SFRP1, FZD1, WNT11, FOSL1*
                 KEGG_PATHWAY   hsa04062:Chemokine signaling pathway           10      3.77            3.97E-02   *CXCL1, ADCY1, DOCK2, CCL23, RAC2, TIAM1, ADCY5, PIK3CD, CCL19, CXCL6*
  Hypo-HGs       KEGG_PATHWAY   hsa04110:Cell cycle                            7       4.38            2.32E-03   *CCNE2, E2F2, PRKDC, CDC20, MCM2, SFN, PTTG1*
                 KEGG_PATHWAY   hsa00140:Steroid hormone biosynthesis          3       1.88            9.07E-02   *CYP17A1, CYP7A1, UGT2B11*

Top five terms were listed on the basis of *P* value if over five terms in the category, Hyper-LGs (hypermethylated, lowly expressed genes), Hypo-HGs (hypomethylated, highly expressed genes).

PPI network construction and cytoHubba analysis
-----------------------------------------------

MDEGs were analyzed by STRING. Ultimately, 264 nodes and 456 edges and 159 nodes and 290 edges were established in the Hyper-LGs and Hypo-HGs networks, respectively. The PPI networks for Hyper-LGs and Hypo-HGs, as shown in Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, exhibited significantly more interactions than expected with a PPI enrichment *P*-value \< 1.0e-16. We then visualized the Hyper-LGs and Hypo-HGs network in Cytoscape and selected hub genes using cytoHubba. A total of five and six hub genes were identified for Hyper-LGs and Hypo-HGs, respectively, by overlap of the top 10 genes according to six ranked methods in cytoHubba (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Hyper-LGs were annotated as prostaglandin-endoperoxide synthase 2 (*PTGS2*), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (*PIK3CD*), C-X-C motif chemokine ligand 1 (*CXCL1*), estrogen receptor 1 (*ESR1*), and matrix metallopeptidase 2 (*MMP2*). Hypo-HGs were annotated as cell division cycle 45 (*CDC45*), denticleless E3 ubiquitin protein ligase homolog (*DTL*), Aurora kinase B (*AURKB*), cyclin dependent kinase inhibitor 3 (*CDKN3*), minichromosome maintenance complex component 2 (*MCM2*), and minichromosome maintenance 10 replication initiation factor (*MCM10*).

![Protein-protein interaction network of hypermethylated, lowly expressed genes. Disconnected nodes were hid in the network.](WJG-24-2605-g002){#F2}

###### 

Hub genes for hypermethylated, lowly expressed genes ranked in cytoHubba

  **Catelogy**         **Rank methods in cytoHubba**                                                              
  -------------------- ------------------------------- -------------- ------------- -------------- -------------- -------------
  Gene symbol top 10   ***PTGS2***                     *ADCY5*        ***PTGS2***   ***PIK3CD***   ***PIK3CD***   ***PTGS2***
  ***PIK3CD***         ***MMP2***                      ***PIK3CD***   ***PTGS2***   ***PTGS2***    ***PIK3CD***   
  *ADCY5*              ***PTGS2***                     ***MMP2***     ***MMP2***    ***MMP2***     ***MMP2***     
  *ADCY1*              ***PIK3CD***                    *ADCY5*        ***ESR1***    ***ESR1***     *PRKG1*        
  ***CXCL1***          *PRKG1*                         *ADCY1*        *PRKG1*       *TLR2*         ***ESR1***     
  ***ESR1***           *ADCY1*                         ***ESR1***     *TLR2*        *SERPINE1*     *FYN*          
  ***MMP2***           ***ESR1***                      ***CXCL1***    *FYN*         *PRKG1*        *RAC2*         
  *FYN*                *FYN*                           *TLR2*         ***CXCL1***   *SNAI1*        *SERPINE1*     
  *TLR2*               ***CXCL1***                     *CALCA*        *SERPINE1*    *CRP*          ***CXCL1***    
  *SERPINE1*           *TLR2*                          *PTGER2*       *ADCY5*       ***CXCL1***    *ADCY5*        

Bold gene symbols were the overlap hub genes in top 10 by six ranked methods respectively in cytoHubba. MNC: Maximum neighborhood component; Degree: Node connect degree; EPC: Edge percolated component.

![Protein-protein interaction network of hypomethylated, highly expressed genes. Disconnected nodes were hid in the network.](WJG-24-2605-g003){#F3}

###### 

Hub genes for hypomethylated, highly expressed genes ranked in cytoHubba

  **Catelogy**         **Rank methods in cytoHubba**                                                           
  -------------------- ------------------------------- ------------- ------------- ------------- ------------- -------------
  Gene symbol top 10   ***CDC45***                     ***CDC45***   ***CDC45***   ***CDC45***   ***CDKN3***   ***CDKN3***
  ***DTL***            ***AURKB***                     ***AURKB***   ***AURKB***   ***CDC45***   *PRKDC*       
  *RACGAP1*            ***DTL***                       ***CDKN3***   ***CDKN3***   ***AURKB***   ***CDC45***   
  ***AURKB***          *RACGAP1*                       ***DTL***     ***DTL***     *PTTG1*       *PTTG1*       
  *CDC20*              *CDC20*                         *RACGAP1*     *RACGAP1*     ***DTL***     ***MCM10***   
  ***CDKN3***          ***CDKN3***                     *CDC20*       *CDC20*       ***MCM2***    *BRCA1*       
  *RRM2*               ***MCM2***                      ***MCM2***    ***MCM2***    ***MCM10***   *PI3*         
  ***MCM2***           *PTTG1*                         *PTTG1*       *PTTG1*       *RACGAP1*     ***AURKB***   
  ***MCM10***          *RRM2*                          *RRM2*        *RRM2*        *CDC20*       ***MCM2***    
  *MKI67*              ***MCM10***                     ***MCM10***   ***MCM10***   *RRM2*        ***DTL***     

Bold gene symbols were the overlap hub genes in top 10 by six ranked methods respectively in cytoHubba. MCC: Maximal cilque centrality; MNC: Maximum neighborhood component; Degree: Node connect degree; EPC: Edge percolated component.

Module analysis
---------------

In total, four modules in the Hyper-LGs network and three modules in the Hypo-HGs network were established as statistically significant. The following GO and KEGG pathways were analyzed (Table [5](#T5){ref-type="table"}). Enrichment analyses for the Hyper-LGs modules demonstrated that the pathways are mainly associated with neuroactive ligand and ECM-receptor interaction, axon guidance, and chemokine signalling pathway. For Hypo-HGs modules, enrichment analysis showed associations with the cell cycle and chemokine signalling pathway. The visualized genes of modules in the Hyper-LGs and Hypo-HGs network are shown in Figure [4A](#F4){ref-type="fig"}-D and Figure [5A](#F5){ref-type="fig"}-C.

![Hypermethylated, lowly expressed genes modules.](WJG-24-2605-g004){#F4}

###### 

Modules analysis of the protein--protein interaction network

  **Category**                                                          **Module**   **Score**   **Nodes**                                                                               **Enrichment and pathway description**                                                                                                     **Genes**
  --------------------------------------------------------------------- ------------ ----------- --------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------
  Hyper-LGs                                                             1            10.00       10                                                                                      GO.0005886: plasma membrane                                                                                                                *ADRB1, VIPR1, PTGDR, SCTR, CALCA, GPR83, ADCY1, ADCY5, PTGER2, PTGER4*
  GO.0007187: G-protein coupled receptor signaling pathway                                                                                                                                                                                                                                                                          
  GO.0004016: adenylate cyclase activity                                                                                                                                                                                                                                                                                            
  has04080: Neuroactive ligand-receptor interaction                                                                                                                                                                                                                                                                                 
  2                                                                     6.00         6           GO.0051953: negative regulation of amine transport                                      *CCL19, ADRA2B, P2RY12, CXCL6, NPY5R, CXCL1*                                                                                               
  GO.0008009: chemokine activity                                                                                                                                                                                                                                                                                                    
  has04062: Chemokine signaling pathway                                                                                                                                                                                                                                                                                             
  3                                                                     5.68         20          GO.0005886: plasma membrane                                                             *OXT, SERPINE1, EDNRB, PTGS2, ADRA1A, IL18, CRP, SOCS3, EFNB3, MMP2, EPHB1, TIAM1, EFNA5, TBXA2R, EPHA2, TLR2, SNAI1, FYN, GNA14, PROK2*   
  GO.0005003: ephrin receptor activity                                                                                                                                                                                                                                                                                              
  GO.0051240: positive regulation of multicellular organismal process                                                                                                                                                                                                                                                               
  hsa04360: Axon guidance                                                                                                                                                                                                                                                                                                           
  4                                                                     4.50         5           GO.0005605: basal lamina                                                                *ITGA9, ITGB8, COL6A2, LAMC2, LAMA2*                                                                                                       
  GO.0030198: extracellular matrix organization                                                                                                                                                                                                                                                                                     
  hsa04512: ECM-receptor interaction                                                                                                                                                                                                                                                                                                
  Hypo-HGs                                                              1            17.56       19                                                                                      GO.0022402: cell cycle process                                                                                                             *CDCA5, KIF14, BRCA1, CENPF, RACGAP1, NEK2, CDKN3, DTL, MCM2, MCM10, CDC45, PTTG1, ANLN, CDC20, RRM2, AURKB, MKI67, STIL, CCNE2*
  GO.0015630: microtubule cytoskeleton                                                                                                                                                                                                                                                                                              
  GO.0003688: DNA replication origin binding                                                                                                                                                                                                                                                                                        
  hsa04110: Cell cycle                                                                                                                                                                                                                                                                                                              
  2                                                                     5.00         5           GO.0007188: adenylate cyclase-modulating G-protein coupled receptor signaling pathway   *CNR1, CCL20, ADCY6, HTR1D, CCL25*                                                                                                         
  hsa04062: Chemokine signaling pathway                                                                                                                                                                                                                                                                                             
  3                                                                     4.50         5           GO.0005615: extracellular space                                                         *REN, PLA2G1B, TIMP1, MMP9, VWF*                                                                                                           

Hyper-LGs: Hypermethylated, lowly expressed genes; Hypo-HGs: Hypomethylated, highly expressed genes.

![Hypomethylated, highly expressed genes modules.](WJG-24-2605-g005){#F5}

DISCUSSION
==========

The occurrence and development of HCC is a complex and multistage process that involves multiple molecular changes of cumulative genetic and epigenetic disorders. As with many other tumors, epigenetic disturbances contribute significantly to the etiology of HCC, especially DNA methylation. Overall, identifying biomarkers in complex diseases, such as HCC, contributes to our understanding of the pathogenesis and diagnosis of diseases\[[@B12]\]. In this study, we identified 266 Hyper-LGs and 161 Hypo-HGs by utilizing public datasets and online bioinformatics tools to analyze microarray profiling data of gene expression (GSE25907) and gene methylation (GSE57956) in HCC. The findings of the interaction network disclosed that the related genes may be involved in molecular regulation of important pathways associated with the development and progression of HCC. Functional and enrichment analyses of the genes verified definite pathways, as well as hub genes associated with methylation, which may offer novel viewpoints for revealing the pathogenesis of HCC.

In view of the analysis in DAVID, Hyper-LGs in HCC, GO enrichment analysis demonstrated BP included response to endogenous and hormone stimulus, cell surface receptor linked signal transduction, and behavior. One fundamental endogenous genotoxic stimulus could cause DNA damage response in cancers\[[@B19]\]. MF enrichment indicated glycosaminoglycan, pattern and polysaccharide binding, and protein tyrosine kinase activity. Previous studies reported that receptor tyrosine kinases restrained tumor angiogenesis and proliferation\[[@B20]\]. In our study, KEGG enrichment analysis revealed the involvement of complement and coagulation cascades, dilated cardiomyopathy, cancer, Wnt, and chemokine signalling. These pathways can promote tumor cell proliferation and metastasis and alter the microenvironment in the pathogenesis of HCC\[[@B20],[@B21]\].

Hypo-HGs in HCC were enriched in the BP of DNA replication, the metabolic process, cell division and cycle, and chromosome organization. MF of GO analysis largely showed enrichments in peptidase and enzyme inhibitor activity, phosphorus-oxygen lyase and cyclase activity, and cytoskeletal protein binding. Previous research showed that the cell cycle played a critical role in cancer by controlling cell division, and there are significant associations among cell proliferation, cell cycle deregulation, and cell cycle-related kinase with HCC incidence and metastasis\[[@B22],[@B23]\]. In addition, cell cycle and steroid hormone biosynthesis pathways were disclosed by KEGG enrichment analysis in present study. It is plausible that metabolites involved in sterol and sphingolipid biosynthesis and phosphoinositides are related to the development of HCC\[[@B24]\]. In summary, understanding biological processes and the signalling pathways involved in MDEGs can help elucidate the pathogenesis of HCC and identify new therapeutic targets.

Based on the PPI network generated for MDEGs, significantly more interactions than expected were observed for Hyper-LGs and Hypo-HGs, with a PPI enrichment *P*-value \< 1.0e-16, and a number of MDEGs appear to be involved in the development and progression of HCC. Finally, we visualized the networks in Cytoscape and identified hub genes for Hyper-LGs using cytoHubba in Cytoscape software: *PTGS2*, *PIK3CD*, *CXCL1*, *ESR1*, and *MMP2*. PTGS2 is a proinflammatory enzyme induced by prostaglandins involved in cell proliferation, tumorigenesis, progression, and metastasis\[[@B25]\] . The PTGS2 gene is commonly up-regulated and plays a role in apoptosis and proliferation of cells in numerous types of cancers\[[@B26],[@B27]\]. It is noteworthy that one meta-analysis showed that the HCC susceptibility is associated with a PTGS2 variant\[[@B28]\]. PIK3CD is a protein coding gene related to transferase activity, transferring phosphorus-containing groups and kinase activity, and involves in lymphocyte activation, proliferation and differentiation\[[@B29]\]. One study found that PIK3CD activating mutations can cause immunodeficiency in patients with a complex phenotype combining defective B and T cell responses\[[@B30]\]. Immunodeficiency plays a crucial role in the progression of many cancers, and immunodeficient patients with HCC exhibit higher morbidity and mortality\[[@B31],[@B32]\]. With *receptor binding* and *chemokine activity*, CXCL1 is a member of the CXC subfamily of chemokines and plays multifarious roles during HCC development, metastasis, and prognosis\[[@B33],[@B34]\]. ESR1, as one of the potential tumor suppressor genes, is a ligand-activated transcription factor closely related with cancer progression. Promoter hypermethylation is a possible mechanism by which ESR1 is silenced in human HCC\[[@B35]\]. MMP2 is among the most well characterized MMPs, and this factor plays essential roles in degrading ECM components. Depending on activation by the PI3K signalling pathway or the ERK and JNK pathways, it has been shown to have critical functions in the progression, invasion, and metastasis of HCC\[[@B36],[@B37]\].

Regarding Hypo-HGs, we identified six hub genes: *CDC45*, *DTL*, *AURKB*, *CDKN3*, *MCM2*, and *MCM10*. CDC45 plays an essential role in the initiation of DNA replication, which is consistent with the biological progress of Hypo-HGs GO analysis. It may be related with the progression of cancers due to induced DNA damage mediating regulation of DNA replication. DTL, also named CRL4 (CDT2), is a ubiquitin-protein ligase complex that plays important roles in the cell cycle, DNA synthesis, and DNA damage\[[@B38]\]. Previous studies disclosed that DTL had an oncogenic function in cancers, including HCC\[[@B39],[@B40]\]. AURKB is a member of the Aurora kinase subfamily of conserved Serine/Threonine kinases with higher expression in tumor cells than normal cells, and its overexpression has been associated with biological characteristics of cancer as well as diagnosis\[[@B41]-[@B43]\]. A member of a protein phosphatase family with dual function in cell cycling, aberrant expression of CDKN3 is associated with carcinogenesis in many cancers, including HCC\[[@B44],[@B45]\]. MCM2 is a highly conserved and essential mini-chromosome maintenance protein involved in the initiation of DNA and eukaryotic genome replication. The expression level of MCM has been associated with outcomes in many cancers and is closely related to HCC recurrence\[[@B46]\]. MCM10 plays a key role in cell cycle progression by mediating DNA replication initiation and elongation as well as preventing DNA damage and protecting genome integrity\[[@B47]\]. Evidence suggests that MCM10 is associated with inherited diseases resulting from genome instability and abnormal proliferation, and the level of MCM10 expression has been correlated with cancer progression and aggressiveness\[[@B48]\]. These findings indicate that the MDEGs in HCC may have a regulatory function in these biological processes and molecular function, and they are reliable with functional enrichment analysis. However, as some genes and pathways identified in the present study have not been formally investigated as targets in the progression of HCC, further research is needed.

Module analysis of the PPI network for Hyper-LGs suggested that the neuroactive ligand and ECM-receptor interaction, axon guidance, and chemokine signalling pathway might be involved in HCC progression. ECM-receptor interaction and axon guidance are critical cellular processes during the development of cancer. In addition, we found the neuroactive ligand-receptor interaction pathway to be related to hypermethylation, potentially resulting in abnormal expression of genes in cancers; more studies are necessary to validate these findings. Module analysis of the PPI network for Hypo-HGs showed complex roles for cell cycle and chemokine signalling pathways during HCC development. The cell cycle is a vital process involving DNA replication and translation, with a tendency for dysregulation in cancer\[[@B22]\]. Interestingly, the chemokine signalling pathway, as an essential process, was disclosed in both Hyper-LGs and Hypo-HGs modules, and this pathway has been shown to influence pathogenesis and metastasis of HCC by altering the tumor microenvironment\[[@B20]\].

In the present study, several limitations should be mentioned. First, the study lacked further experimental verification of the effects of aberrant methylation on gene expression and functions in HCC. Second, we did not investigate clinical parameters and prognosis, owing to the accessibility of data by bioinformatics arrays and tools. Third, as only two microarray profiles were analyzed, the sample size was not sufficiently large; thus, large-sample studies are required to validate the findings. In addition, HCC is closely related to hepatitis B and C, chronic alcoholism, tobacco smoking, and aflatoxins, and etiological factors were not analyzed in our study. Therefore, supplementary molecular experiments should be encouraged to verify further the results of our investigation.

In conclusion, using a series of bioinformatics databases and tools, we found that interactions among MDEGs of different functions and signalling pathways are related to the pathogenesis of HCC. Hub genes for Hyper-LGs of HCC included *PTGS2*, *PIK3CD*, *CXCL1*, *ESR1*, and *MMP2*; such genes for Hypo-HGs included *CDC45*, *DTL*, *AURKB*, *CDKN3*, *MCM2*, and *MCM10*. As special biomarkers based on aberrant methylation, these hub genes might be useful for accurate diagnosis and treatment of HCC. This study provides hypothetical and biological characteristic insight into the pathogenesis of HCC. Additional molecular-level studies are needed to confirm the identified genes and pathways in HCC and to elucidate potential mechanisms.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Pathogenesis of hepatocellular carcinoma (HCC) is a complicated biological process involving epigenetic and genetic changes. Most prior studies, however, mainly focused on either gene expression or methylation data but not the association and did not perform a conjoint analysis. The detection of methylated-differentially expressed genes (MDEGs) and a better understanding of their characteristics may be useful for discovering the molecular mechanism and pathogenesis of HCC.

Research motivation
-------------------

In view of the insights from previous studies that MDEGs can be detected concurrently by joining gene expression and methylation microarray data, we explored the interaction network of differentially expressed genes and differentially methylated genes along with interrelated signalling pathways to find novel insights into the biological characteristics and pathways of methylated-differentially expressed genes in HCC.

Research objectives
-------------------

The objective was to discover MDEGs in HCC, and explore relevant hub genes and potential pathways to make notional viewpoints available for the development and progression of HCC.

Research methods
----------------

We analyzed differentially methylated genes and differentially expressed genes using a series of bioinformatics databases and tools including GEO Datasets, DAVID, STRING, and Cytoscape.

Research results
----------------

We categorized 266 hypermethylated, lowly expressed genes (Hyper-LGs) and 161 hypomethylated, highly expressed genes (Hypo-HGs) in GO, KEGG, and PPI analyses. Hyper-LGs mainly refer to endogenous and hormone stimulus, cell surface receptor linked signal transduction, and behavior, while Hypo-HGs refer to DNA replication, metabolic processes, cell cycle, and cell division. Pathway analysis showed that Hyper-LGs were enriched in cancer, Wnt, and chemokine signalling pathways, while Hypo-HGs were related to cell cycle and steroid hormone biosynthesis pathways. Based on PPI networks, *PTGS2*, *PIK3CD*, *CXCL1*, *ESR1*, and *MMP2* were identified as hub genes for Hyper-LGs, and *CDC45*, *DTL*, *AURKB*, *CDKN3*, *MCM2*, and *MCM10* were identified for Hypo-HGs by combining six ranked methods of cytoHubba.

Research conclusions
--------------------

We found that interactions among MDEGs of different functions and signalling pathways are related to the pathogenesis of HCC by a series of bioinformatics databases and tools. Hub genes for Hyper-LGs of HCC included *PTGS2, PIK3CD, CXCL1, ESR1*, and *MMP2*; such genes for Hypo-HGs included *CDC45, DTL, AURKB, CDKN3, MCM2*, and *MCM10*. As special biomarkers based on aberrant methylation, these hub genes might be useful for accurate diagnosis and treatment of HCC. This study provides hypothetical and biological characteristic insight into the pathogenesis of HCC.

Research perspectives
---------------------

The present findings indicate that the MDEGs in HCC can have a regulatory function in biological processes and molecular function and that they are reliable with functional enrichment analysis. As some genes and pathways identified in the present study have not been formally investigated as targets in the progression of HCC, further research is needed.
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